Avalo Therapeutics, Inc. Earnings Per Share Diluted

• Avalo Therapeutics, Inc. showed an increase of +72.1% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2015 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2015 to 2025), Avalo Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 24.0%.
• Historical annual values: Fiscal year 2025: $5.84 (loss) per share | Fiscal year 2024: $20.91 (loss) per share | Fiscal year 2023: $113.58 (loss) per share | Fiscal year 2022: $1,063.00 (loss) per share | Fiscal year 2018: $1.20 (loss) per share | Fiscal year 2017: $0.42 per share | Fiscal year 2016: $1.87 (loss) per share | Fiscal year 2015: $4.71 (loss) per share.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026